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Programmed necrosis or necroptosis is an inflam-
matory form of cell death that critically requires
the receptor-interacting protein kinase 3 (RIPK3).
Here we showed that RIPK3 controls a separate,
necrosis-independent pathway of inflammation by
regulating cytokine expression in dendritic cells
(DCs). Ripk3/ bone-marrow-derived dendritic cells
(BMDCs) were highly defective in lipopolysaccharide
(LPS)-induced expression of inflammatory cyto-
kines. These effects were caused by impaired NF-
kB subunit RelB and p50 activation and by impaired
caspase 1-mediated processing of interleukin-1b (IL-
1b). This DC-specific function of RIPK3 was critical
for injury-induced inflammation and tissue repair in
response to dextran sodium sulfate (DSS). Ripk3/
mice exhibited an impaired axis of injury-induced
IL-1b, IL-23, and IL-22 cytokine cascade, which
was partially corrected by adoptive transfer of wild-
type DCs, but not Ripk3/DCs. These results reveal
an unexpected function of RIPK3 in NF-kBactivation,
DC biology, innate inflammatory-cytokine expres-
sion, and injury-induced tissue repair.
INTRODUCTION
Programmed necrosis or necroptosis is a nonapoptotic form of
cell death with important functions in infectious and sterile
inflammation. Similar to apoptosis, necroptosis can be induced
by diverse signals, including those that stimulate tumor necrosis
factor (TNF) receptor-like death receptors, Toll-like receptors
(TLRs) 3 and 4, and the T cell receptor. The receptor-interacting
protein kinase 3 (RIPK3) is a critical regulator of necroptosis
(Moriwaki and Chan, 2013). RIPK3 interacts with its upstream
kinase RIPK1 via the RIP-homotypic interaction motif (RHIM)
to form an amyloid-like complex termed the necrosome, which
is critical for recruitment of the RIPK3 substrate MLKL (mixed-
lineage kinase domain-like) (Li et al., 2012). Activated MLKL
forms oligomers and translocates to the plasma membrane
(Batinic-Haberle et al., 2009; Cai et al., 2014; Chen et al.,
2014; Dondelinger et al., 2014). Activated MLKL oligomers
eventually cause membrane rupture and the release of
danger-associated molecular patterns (DAMPs) to promote in-
flammatory reactions. RIPK3-mediated necroptosis is optimallytriggered when caspase 8 or its adaptor, FADD (Fas-associated
via death domain) is inactivated. For example, tissue-specific
deletion of FADD or caspase 8 in keratinocytes or intestinal
epithelium led to spontaneous inflammation that is rescued by
inactivation of RIPK3 (Bonnet et al., 2011; Gu¨nther et al.,
2011; Welz et al., 2011). These results support the notion that
RIPK3-dependent necroptosis is a key driver of inflammatory
diseases.
Although the current model predicts that the proinflammatory
function of RIPK3 is largely due to its role in necroptosis, it is
noteworthy that overexpression of RIPK3 in different settings
could either enhance or inhibit NF-kB activity (Kaiser et al.,
2008; Kasof et al., 2000; Meylan et al., 2004; Sun et al., 1999;
Yu et al., 1999). NF-kB is a latent transcription factor that medi-
ates inflammatory cytokine expression in response to TNF-like
cytokines and TLR stimulation. Hence, it is possible that RIPK3
facilitates inflammation through necrosis-mediated release of
damage-associated molecular patterns (DAMPs) as well as
NF-kB induction of inflammatory cytokines. However, TNF-
or LPS-induced inhibitor of kB a (IkBa) phosphorylation and
degradation in Ripk3/ mouse embryonic fibroblasts (MEFs)
and bone-marrow-derived macrophages (BMDMs) were normal
(Newton et al., 2004). As such, it is widely accepted that RIPK3 is
dispensable for NF-kB activation.
More recently, RIPK3 has been shown to facilitate pro-IL-1b
processing in macrophages and dendritic cells (DCs) lacking
cellular inhibitor of either apoptosis 1 (cIAP1), cIAP2, and
X-linked IAP (XIAP) (Vince et al., 2012) or caspase 8 (Kang
et al., 2013). RIPK3-dependent pro-IL-1b processing under
these conditions was reported to be independent of necroptosis.
Because these observations were made under conditions with
artificial inactivation of IAPs or caspase 8, it remains unclear
whether RIPK3 can truly control inflammation independently of
necroptosis in more physiological settings.
Here, we report that RIPK3 has a critical role in promoting
injury-induced reparative inflammation in a mouse model of
colitis. We showed that RIPK3 is crucial for induction of an axis
of IL-23, IL-1b, and IL-22 in response to injury to the colon.
RIPK3 ensured optimal IL-23 and IL-1b expression by promoting
nuclear activation of RelB-p50 and caspase 1-mediated pro-IL-
1b processing in DCs. Cytokine expression was not affected
in Ripk3/ macrophages. Adoptive transfer of wild-type (WT)
bone-marrow-derived dendritic cells (BMDCs), but not Ripk3/
or Ripk3/Casp8/ BMDCs, partially restored defective IL-23,
IL-1b, and IL-22 expression in Ripk3/ mice. These results
reveal an unexpected aspect of RIPK3 biology in regulating
NF-kB activation, inflammatory cytokine expression, and DC
functions.Immunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc. 567
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Figure 1. RIPK3 Protects against DSS-
Induced Colitis
(A) Body weight and (B) colon length of 3%-DSS-
treated Ripk3/ (KO) and littermate Ripk3+/+ (WT)
mice on day 15. (C) Histological scores of the distal
colon of 3%-DSS-treated mice on day 15 were
measured. Representative microscopic pictures
of H&E-stained colons from control mice and the
mice treated with DSS for 15 days are shown on
the right. The scale bar represents 75 mm. The
number in parentheses represents the number of
mice used in each group. Results shown are
mean ± SEM. Asterisks indicate p < 0.05. Results
are pooled from three independent experiments.
See also Figure S1.
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Non-necrotic Inflammatory Function of RIPK3RESULTS
Ripk3–/– Mice Are Highly Susceptible to Colitis
Mice with conditional deletion of FADD or caspase 8 in the intes-
tinal epithelium suffer from spontaneous colitis that is rescued by
ablation of RIPK3, suggesting that RIPK3 promotes inflamma-
tory bowel diseases (Gu¨nther et al., 2011; Welz et al., 2011).
We asked whether RIPK3 is a promoter of colitis in the presence
of intact apoptosis machinery by treating mice with DSS for
7 days, followed by recovery in normal drinking water for
7 days. In Ripk3+/+ WT mice, this treatment led to loss of body
weight and subsequent recovery around day 10 as the tissue
injury was repaired (Figure 1A). Contrary to expectation, litter-
mate Ripk3/ mice (KO) developed more severe colitis in
response to DSS, as determined by weight loss and shortening
of the colon (Figures 1A and 1B). Although separately housed
Ripk3+/+ and Ripk3/ mice exhibited subtle differences in their
intestinal microflora (Figure S1A and Table S1 available with
this article online), they responded similarly to mice that were
nursed by the same foster mother from birth or those that were
cohoused for four weeks (Figures S1B–S1D). These results indi-
cate that Ripk3/ mice do not have transmissible colitogenic
microbiota. Moreover, although the difference between
Ripk3/ and Ripk3+/ was not statistically significant (p =
0.0589), Ripk3+/ mice showed intermediate body-weight loss
(Figure S1E). This indicates that the gene dosage of RIPK3
may be important for protection against DSS-induced colitis.
Basal colon histology was normal in Ripk3/ mice (Figure 1C).
However, increased injury-induced inflammation and ulcers
were apparent in DSS-treated Ripk3/ mice on day 15 (Fig-568 Immunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc.ure 1C). Hence, unlike in mice with condi-
tional deletion of FADD or caspase 8
in the intestine, in wild-type mice RIPK3
limits the extent of chemically induced
colitis.
RIPK3 Is Required for Tissue
Repair, but not DSS-Induced Tissue
Injury
The increased colonic injury in Ripk3/
mice was inconsistent with the purported
effect of RIPK3 on promoting injury
of the colon epithelium. TdT-mediateddUTP nick end labeling (TUNEL) staining, which detects both
apoptosis and necrosis (Figure S2A) (Vanden Berghe et al.,
2013), was most prominent in colon epithelial cells on day 4 after
DSS treatment, when RIPK3 expression was minimal. Impor-
tantly, the number of TUNEL+ cells was similar in Ripk3/ and
Ripk3+/+ mice (Figure 2A). However, active caspase 3 staining
was absent in the intestine of DSS-treated mice (Figure S2B),
whereas anti-Fas antibody strongly induced TUNEL and active
caspase 3 staining in the liver (Figure S2C). In addition, mononu-
clear cells in the lamina propria also did not exhibit increased
cell death in response to DSS (Figure S2D). These results
suggest that DSS primarily induces caspase-independent injury
in a RIPK3-independent manner.
We found that RIPK3 mRNA expression in the colon was
strongly induced by DSS on day 7 and peaked on day 10,
when themice had beenweaned fromDSS (Figure 2B). Immuno-
histochemical staining showed that RIPK3 expression was
elevated in the colon epithelium (arrows) as well as in mononu-
clear cells in the lamina propria (arrowheads) (Figure 2C and
Figure S2E). Because RIPK3 was expressed in mononuclear
cell infiltrates and intestinal epithelium, we generated radiation
BM chimeras to ascertain the relative contribution of RIPK3
in these compartments (Figure S2F). Compared with control
Ripk3/ mice receiving Ripk3/ BM cells (Figure 2D, green
and red curves), Ripk3+/+ host reconstituted with Ripk3/ BM
cells developed similarly severe colitis. Ripk3/ mice reconsti-
tuted with Ripk3+/+ BM cells showed intermediate body-weight
loss, suggesting that RIPK3 also had a minor role in epithelial tis-
sues (Figure 2D, blue curve). Measurement of colon length and
histological scores confirmed similar patterns of disease severity
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Figure 2. RIPK3 in Hematopoietic Cells Is Required for Protection against DSS-Induced Colitis
(A) The number of TUNEL+ cells/visual field in colons from control mice andmice treated with DSS for 4 days was enumerated. Representative pictures of TUNEL
staining are shown. Arrows indicate TUNEL-positive cells.
(B) Relative mRNA expression of Ripk3 in colon tissues of DSS-treated Ripk3+/+ mice (n = 4–8).
(C) RIPK3 expression in colon sections. Arrows and arrowheads indicate RIPK3+ colon epithelial cells and mononuclear cells in lamina propria, respectively.
Magnified views of the marked areas are shown in the lower panels.
(D–F) Bone marrow chimeras of the indicated genotypes were fed 3% DSS water, and (D) body weight, (E) colon length, and (F) histological scores were
measured. The numbers in parentheses represent the number of mice used in each group. White and black bars show Ripk3+/+ (WT) and Ripk3/ (KO) mice,
respectively. Scale bars represent 75 mm. Results shown are mean ± SEM. Asterisks indicate p < 0.05 (D, green line versus black or blue line). Results are pooled
from three independent experiments (D–F). See also Figure S2.
Immunity
Non-necrotic Inflammatory Function of RIPK3in the different chimeras (Figures 2E and 2F). Hence, unlike in
mice with intestinal-epithelium-specific deletion of FADD or cas-
pase 8, in wild-type mice RIPK3 expression in hematopoietic
cells is critical for limiting the extent of DSS-induced colitis.RIPK3 Is Essential for Injury-Induced IL-1b, IL-23, and
IL-22 Expression
Increased proliferation of epithelial cells in the crypt is a hallmark
of injury-induced repair response (Iizuka and Konno, 2011). WeImmunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc. 569
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Figure 3. RIPK3 Promotes Repair of the
Intestinal Epithelium.
(A) The number of Ki67+ cells/colon crypt from
control mice and the mice treated with DSS for
7 days was enumerated. Representative pictures
of Ki67 staining are shown on the right. Scale
bars = 75 mm. (B) Relative mRNA (n = 5–12) and (C)
protein expression (n = 3–6) in DSS-treated
Ripk3+/+ (WT) and Ripk3/ (KO) colons on day 7.
(D) T cell andmacrophage recruitment to the colon
after DSS treatment (day 7). (E) T cell, macro-
phage, and DC populations in the colonic lamina
propria after DSS treatment (day 7). CD3+ cells
and CD3-CD19-CD11cCD103CD11b+ cells
were defined as T cells and macrophages,
respectively. CD11c+ cells were defined as DCs.
The various DC subsets defined by cell-surface
markers are also shown. Data were obtained from
four mice for each genotype; two mice were
pooled. Results shown are means ± SEM. Aster-
isks indicate p < 0.05. See also Figure S3.
Immunity
Non-necrotic Inflammatory Function of RIPK3found that cell proliferation in the epithelial crypts as measured
by Ki67 staining was reduced in Ripk3/ mice (Figure 3A).
Moreover, expression of repair-associated inflammatory cyto-
kines such as IL-6, cyclooxygenase-2 (Cox2), and epithelial
growth factor receptor ligand Epiregulin (Ereg) was also reduced
in the colon of Ripk3/ mice (Figures 3B–3C and Figure S3A)
(Brandl et al., 2010; Fukata et al., 2006; Grivennikov et al.,
2009). Because the numbers of T cells, macrophages, and
DCs recruited to the inflamed intestine were similar between
Ripk3/ and Ripk3+/+ mice on day 7 (Figures 3D and 3E; see
also Figure S3B), the reduced cytokine expression and repair-
associated proliferation in Ripk3/ mice were unlikely to be
due to impaired recruitment of immune effectors. Rather, these
results implicate that an intrinsic defect in cytokine expression
by hematopoietic cells is the underlying cause of the failed tissue
repair response in Ripk3/ mice.570 Immunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc.IL-22 is a critical cytokine for tissue
repair and homeostasis in the intestine
(Cox et al., 2012; Huber et al., 2012; Miz-
oguchi, 2012; Monteleone et al., 2011;
Pickert et al., 2009; Sugimoto et al.,
2008; Zenewicz et al., 2008). We found
that the expression of IL-22 was severely
blunted in Ripk3/ mice (Figure 4A).
However, expression of IL-22 binding
protein (IL-22BP) and IL-22 receptor
alpha 1 (IL-22RA1) was unaffected in
Ripk3/ mice (Figure S4A). Consistent
with diminished IL-22 signaling, expres-
sion of the antimicrobial protein Reg3b,
a transcriptional target of IL-22, and
phosphorylation of signal transducer
and activator of transcription 3 (STAT3)
were greatly diminished in Ripk3/
mice (Figure 4B and Figure S4B). Admin-
istration of IL-22-Fc, but not isotype
control IgG, partially rescued the severe
colitis in Ripk3/ mice (Figures 4C and
4D). However, although colon length was significantly restored,
rescue of body-weight loss was not statistically significant.
This indicates that although a failure to upregulate IL-22 is partly
responsible for the susceptibility of Ripk3/ mice to colitis,
other factors might also be involved.
Retinoic-acid-receptor-related orphan receptor gamma t
(RORgt)-positive innate lymphoid cells (ILCs) are the major pro-
ducers of IL-22 (Cox et al., 2012; Sawa et al., 2011; Spits and Cu-
pedo, 2012). We found that normal numbers of ILCs developed
in Ripk3/ mice (Figure S4C) and that Ripk3/ ILCs produced
IL-22 normally in response to exogenous IL-23 (Figures 4E and
4F). This indicates that defective IL-22 expression was due to
upstream signals that stimulate IL-22 expression, and not to
cell-intrinsic ILC defects. IL-23 and IL-b are strong inducers of
IL-22 and have been implicated in the pathogenesis of DSS-
induced colitis (Becker et al., 2006; Bersudsky et al., 2014;
A B C D
E F
Figure 4. RIPK3 Protects against DSS-Induced Colitis through IL-22 Expression
(A and B) Relative mRNA expression of (A) Il22 and (B) Reg3b in colon tissues of DSS-treated Ripk3+/+ (WT) and Ripk3/ (KO) mice (day 7, n = 5–12).
(C and D) Body weight (C) and colon length (D) on day 15 in the mice treated with 50 mg IL-22-Fc or isotype control IgG. The number in parentheses represents the
number of mice used in each group.
(E and F) Splenocytes were stimulatedwith IL-23 in the presence of PMA and Ionomycin. (E) IL-22 expression was determined by ELISA (n = 4). (F) Representative
FACSplots showing IL-22 expression in splenic ILCs (CD3CD19-CD11bIL-7R+CD4+CD25+ cells). The percentage of IL-22+ cells in splenic ILCs is shown on the
right (n = 4). Results shown are means ± SEM. Asterisks indicate p < 0.05. See also Figure S4.
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Non-necrotic Inflammatory Function of RIPK3Cox et al., 2012; Lee et al., 2013; Reynders et al., 2011).
We found that induction of both cytokines (Figure 5A and
Figure S5A), but not their receptors (Figure S5B), was greatly
diminished in the colon of Ripk3/ mice. Significantly, co-
administration of IL-23 and IL-1b partially restored IL-22 expres-
sion, body-weight loss, and colon shortening in Ripk3/ mice
(Figures 5B–5D). By contrast, neither cytokine alone was suffi-
cient to ameliorate colitis in Ripk3/ mice (Figures S5C–S5F).
Hence, an impaired IL-23, IL-1b, and IL-22 axis contributes to
the severe colitis in Ripk3/ mice.
RIPK3 Is Required for Cytokine Expression in DCs, but
Not Macrophages
DCs and macrophages are powerful sentinels of the immune
system that control many aspects of inflammation through cyto-
kine production, including that of IL-1b and IL-23. We used LPS,
a TLR4 ligand, to mimic stimulation of DCs and macrophages
by commensal bacteria during intestinal injury. LPS-induced
expression of IL-23, IL-1b, TNF, andmonocyte chemotactic pro-
tein-1 (MCP-1) was severely inhibited in Ripk3/ BMDCs (Fig-
ure 6A and Figures S6A and S6B). This is in contrast to Ripk3/BMDMs, which produced normal amounts of cytokines in
response to LPS (Figures S6C and S6D). The reduced cytokine
expression in Ripk3/ BMDCs was not caused by reduced
release of DAMPs given that neither Ripk3+/+ nor Ripk3/
BMDCs exhibited appreciable cell death in response to LPS
alone (Figure S6E). By contrast, Ripk3/ BMDCs were resistant
to necrosis induced by LPS and pancaspase inhibitor z-VAD-
fmk, as expected (Figure S6E). In addition, supernatants from
cells in which necrosis had been induced by repeated freeze-
thaw cycles did not affect LPS-induced cytokine expression by
BMDCs (Figure S6F). Moreover, although RIPK3- and RIPK1-
specific kinase inhibitors blocked necroptosis (Figure S6G),
they did not suppress LPS-induced cytokine expression by
BMDCs (Figures S6H and S6I). Hence, unlike necroptosis,
LPS-induced cytokine expression does not require the kinase
activities of RIPK1 and RIPK3. These results also reinforce the
notion that defective necrosis does not contribute to the blunted
cytokine expression by Ripk3/ BMDCs.
To test whether defective cytokine expression by DCs is func-
tionally relevant to colitis induction in Ripk3/ mice, we adop-
tively transferred Ripk3+/+ or Ripk3/ BMDCs into DSS-treatedImmunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc. 571
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Figure 5. RIPK3 Controls IL-22 Expression
through IL-23 and IL-1b Induction
(A) Relative mRNA expression of Il23p19 and Il1b
in colon tissues of DSS-treated Ripk3+/+ (WT) and
Ripk3/ (KO) mice (day 7, n = 5-12). (B) Il22
expression on day 7, (C) body weight, and (D)
colon length on day 15 in the mice treated with
PBS or amixture of IL-1b and IL-23. The number in
parentheses represents the number of mice used
in each group. Results shown are means ± SEM.
Asterisks indicate p < 0.05 (C, blue line versus red
line). See also Figure S5.
Immunity
Non-necrotic Inflammatory Function of RIPK3Ripk3/ mice. IL-22, IL-23p19, and IL-1b expression was
significantly restored by Ripk3+/+, but not Ripk3/, BMDCs
(Figure 6B). Because DCs developed normally in the lamina
propria of Ripk3/ mice (Figure 3E), these results strongly
support the notion that RIPK3 expression enables DCs to sense
and to respond to intestinal injury through expression of IL-23
and IL-1b.
RIPK3 Controls RelB-p50 and Caspase 1 Activation in
BMDCs
NF-kB is themajor driver for expression of many of the cytokines
that were defective in Ripk3/ mice and BMDCs (Oeckinghaus
and Ghosh, 2009). Previous studies with Ripk3/ fibroblasts
and BMDMs showed that RIPK3 was dispensable for IkBa phos-
phorylation and degradation (Newton et al., 2004). Consistent
with this early report, the initial LPS-induced phosphorylation
and degradation of IkBa and IkBε were normal in Ripk3/
BMDCs (Figure 6C and Figure S6J). The slightly higher basal
expression of IkBε in Ripk3/ BMDCs might contribute to
the impaired RelB-p50 nuclear translocation. Moreover, LPS-
induced phosphorylation of the upstream kinases of IkB, IKKa,
and IKKb was normal in Ripk3/ BMDCs (Figure S6J). In addi-
tion, activation of the Mitogen-activated protein (MAP) kinases
extracellular signal regulated kinase (Erk) and c-Jun N-terminal
kinase (JNK) was not decreased in Ripk3/ BMDCs (Fig-
ure S6J). Although the initial IkBa phosphorylation and degra-
dation was unchanged, IkBa phosphorylation was greatly
diminished at 2 and 6 hr, and NF-kB-dependent re-expression572 Immunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc.of IkBa at 6 hr was impaired in Ripk3/
BMDCs (Figure 6C, lanes 7 and 14). The
late impairment of NF-kB activation
might be due to reduced autocrine TNF
signaling or defects in NF-kB activation
downstream of IkBa. Basal and LPS-
induced nuclear translocation of RelB
and p50 was diminished in Ripk3/
BMDCs (Figure 6D). Quantification by
FlowSight analysis confirmed that the
percentage of Ripk3/ BMDCs with
RelB nuclear translocation was signifi-
cantly lower than the percentage in
Ripk3+/+ BMDCs (Figure 6E). By contrast,
nuclear RelA and p52 were unaffected in
Ripk3/ BMDCs (Figure 6D). However,
nuclear cRel was slightly increased inRipk3/ BMDCs. Immunodepletion followed by electrophoretic
mobility-shift assay (EMSA) showed that nuclear DNA binding
activity of the RelB-p50 dimer, but not RelA-p50, was strongly
reduced in Ripk3/ BMDCs (Figure S6K). Unlike LPS, TNF
induced both normal nuclear translocation of RelB and p50
and normal expression of IL-23 in Ripk3/BMDCs (Figure S6L).
These results are consistent with a published report that RelB
regulates expression of IL-23p19, TNF, and IL-1b in BMDCs
downstream of TLRs (Shih et al., 2012). In contrast, expression
of IL-12p35, a cRel-regulated cytokine (Shih et al., 2012), was
normal in Ripk3/ BMDCs (Figure S6M). Collectively, these
results strongly support the notion that RIPK3 specifically regu-
lates expression of a specific set of cytokines in BMDCs by regu-
lating RelB-p50 activation.
RelB is a ‘‘noncanonical’’ NF-kB subunit that dimerizes with
p52 and is normally regulated through processing of p100 into
p52 (Oeckinghaus and Ghosh, 2009). However, in DCs, RelB
forms a dimer with p50 and is regulated by its binding to IkB pro-
teins in a ‘‘canonical’’ manner (Figure 6F) (Shih et al., 2012).
Because RelB andRIPK3weremore highly expressed in BMDCs
than in BMDMs (Figure S6N), the DC-specific function of RIPK3
might be explained by RIPK3-specific effects on RelB. Reactive
oxygen species (ROS) are known to regulate NF-kB nuclear
translocation and activation (Morgan and Liu, 2011). Because
RIPK3 is a strong inducer of ROS downstream of TNFR and
TLRs (Cho et al., 2009; Lushchak, 2012; Vince et al., 2012), we
tested the role of ROS in RelB-p50 nuclear translocation. Indeed,
we found that LPS stimulated ROS production in Ripk3+/+, but
BA
C D
E
F
HG I
Figure 6. RIPK3 Controls Cytokine Production in DCs by Regulating RelB and p50 Nuclear Translocation
(A) IL-23 and IL-1b secretion by BMDCs treated with LPS for 6 hr (n = 4).
(B) Ripk3+/+ (WT, n = 10) or Ripk3/ (KO, n = 8) BMDCs were injected to Ripk3/mice on day 5. PBS was injected into control mice (Ripk3+/+, n = 14; Ripk3/,
n = 8). Cytokine expression in the colon on day 7 is shown. Gene expression in theRipk3/ PBS control was defined as 1. ‘‘C’’ indicates control. The results were
pooled from two independent experiments.
(C and D) Whole-cell extracts (WCEs) (C) and nuclear extracts (D) from BMDCs treated with 100 ng/ml LPS were subjected to immunoblot analyses. p-IkBa =
phopho IkBa.
(E) BMDCs stimulated with 100 ng/ml LPS for 2 hr were subjected to intracellular staining for RelB (n = 8). Representative pictures of cytoplasmic (top) and nuclear
(bottom) RelB localization are shown on the right. Scale bars represent 20 mm.
(F)WCEs fromRipk3+/+ andRipk3/BMDCs treatedwith 100 ng/ml LPS for 2 hr were subjected to immunoprecipitation with anti-RelB antibody and subsequent
immunoblot analyses.
(G) Relative mean fluorescence intensity (MFI) of the ROS reactive dye CM-H2DCFDA was measured in BMDCs treated with 100 ng/ml LPS for 6 hr (n = 4).
(H and I) NF-kB nuclear translocation (2 hr) (H) and IL-23 secretion (3 hr, n = 4) (I) by Ripk3+/+ BMDCs treated with LPS in the presence of NAC. Results shown are
means ± SEM. Asterisks indicate p < 0.05. See also Figure S6.
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Figure 7. RIPK3 Controls IL-1b Secretion in DCs through Inflamma-
some Activation
(A) Relative mRNA expression of Il1b in Ripk3+/+ (WT) and Ripk3/ (KO)
BMDCs treated with LPS for 6 hr (n = 4).
(B) WCE from BMDCs treated with LPS for an hour was tested by immunoblot
analysis.
(C) Cytokine expression in BMDCs pretreated with 5 mM z-YVAD-fmk and then
stimulated with LPS for 6 hr (n = 2).
(D) Relative Il23p19 expression in BMDCs pretreated with IL-1RA for an hour
and then stimulated with LPS for 6 hr (n = 3).
(E) Caspase 1 activation (1 hr) and (F) IL-1b secretion (3 hr, n = 4) in Ripk3+/+
BMDCs treated with LPS in the presence of NAC. Results shown are
means ± SEM. Asterisks indicate p < 0.05. See also Figure S7.
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acetyl cysteine (NAC) and superoxide dismutase (SOD) mimetic
MnTBAP inhibited LPS-induced accumulation of nuclear RelB
and p50 but had no effects on nuclear RelA, c-Rel, or p52 (Fig-
ures 6H and 6I and Figure S6O). In contrast, the vitamin E analog
Trolox had no effect on RelB or p50 nuclear translocation
(Figure S6O). These results suggest that RIPK3 regulates RelB-
p50 nuclear translocation in BMDCs through the induction
of ROS.
Although mature IL-1b secretion was completely abrogated
(Figure 6A), IL-1b mRNA was still induced more than 100-fold
in Ripk3/ BMDCs (Figure 7A). Consistent with the strong IL-574 Immunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc.1b mRNA expression, LPS-induced pro-IL-1b expression was
normal in Ripk3/ cell lysates (Figure 7B, top panel). Mature
IL-1b secretion requires processing of pro-IL-1b by caspase 1,
the active component of the inflammasome (Latz et al., 2013).
In DCs, however, LPS alone was sufficient to induce a low
amount of caspase-1-dependent IL-1b secretion in the absence
of a second inflammasome-activating signal (Figure 7C) (He
et al., 2013). This low amount of LPS-induced caspase 1 activa-
tion, as measured by cleavage into the p10 fragment, was abol-
ished in Ripk3/ BMDCs (Figure 7B). Reduced IL-1b secretion
and caspase 1 activation were also observed in Ripk3/
BMDCs when the inflammasome was activated by ATP (Fig-
ure S7A). However, neither the caspase 1 inhibitor z-YVAD-
fmk, which greatly reduced mature IL-1b secretion (Figure 7C),
nor the IL-1R antagonist Anakinra (Figure 7D) affected LPS-
induced cytokine expression (Figure S7B), so defective IL-1b
expression did not contribute to impaired NF-kB activation and
cytokine expression in Ripk3/ BMDCs. The antioxidant NAC
inhibited caspase 1 activation and IL-1b secretion (Figures 7E
and 7F) (Vince et al., 2012). Injection of NAC into DSS-treated
mice strongly suppressed IL-1b and, to a lesser extent, IL-23
and IL-22 expression (Figure S7C). However, Trolox did not
affect IL-1b secretion, and MnTBAP actually increased IL-1b
secretion (Figure S7D). Hence, although RIPK3-dependent
ROS production might contribute to NF-kB activation, cytokine
expression, and pro-IL-1b processing in response to intestinal
injury, other mechanisms might also be involved.
Genetic evidence indicates that RIPK3-dependent necropto-
sis and IL-1b secretion are optimally induced by ablation of
caspase 8 (Gu¨nther et al., 2011; Kang et al., 2013). Given this
relationship, one might speculate that enhanced caspase 8
activation is responsible for the impaired cytokine response in
Ripk3/ BMDCs. However, LPS-induced caspase 8 activation
was not increased but rather was abrogated in Ripk3/ BMDCs
(Figure S7E). Moreover, IL-1b and IL-23p19 expression were
equally defective in Ripk3/Casp8/ BMDCs (Figure S7F).
In fact, LPS-induced IL-23p19 expression was further reduced
in Ripk3/Casp8/ BMDCs compared with Ripk3/ BMDCs.
Furthermore, Ripk3/Casp8/ BMDCs failed to rescue cyto-
kine expression in DSS-treated Ripk3/ mice (Figure S7G).
Thus, impaired NF-kB activation and pro-IL-1b processing in
Ripk3/ BMDCs was not caused by hyperactivation of caspase
8. Rather, our results are consistent with a recent report that
caspase 8 has a key role in priming the inflammasome (Allam
et al., 2014). Taken together, these results indicate that RIPK3
can promote inflammatory cytokine expression independently
of necroptosis. Moreover, this necroptosis-independent activity
is critical for injury-induced tissue repair.
DISCUSSION
RIPK3-dependent necrosis is widely believed to contribute to
detrimental pathologies. In contrast to this view, we have shown
that RIPK3 is profoundly important for injury-induced inflamma-
tion and tissue repair in the intestine, in part through an IL-23, IL-
1b, and IL-22 axis. The role of IL-23 in DSS-induced colitis has
been controversial. In one report, Il23p19/ mice developed
more severe colitis in response to DSS (Becker et al., 2006).
However, another report found that IL-23 and IL-23R could either
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ence of an intact adaptive immune cell compartment (Cox
et al., 2012). Our results indicate that the early induction of IL-
23 and IL-1b is crucial for IL-22 expression and initiation of the
tissue repair program. It is noteworthy that although IL-22 is
important for tissue repair, chronic expression of IL-22 is detri-
mental to intestinal homeostasis and can promote tumorigenesis
(Huber et al., 2012). As such, the timing and duration of cytokine
action might dictate the biological outcome and explain the
discrepant observations for IL-23 in different studies.
Besides the IL-1b, IL-23, and IL-22 axis, a pathway involving
the NLRP3 (nucleotide-binding domain and leucine-rich-
repeat-containing family, pyrin-domain-containing 3) inflam-
masome, IL-18, and Myd88 (myeloid differentiation primary
response gene 88) has also been linked to intestinal tissue repair
and protection against DSS-induced colitis. Il18/, Myd88/,
Nlrp3/, Asc/, and Casp1/ mice are highly sensitive to
DSS-induced colitis (Allen et al., 2010; Dupaul-Chicoine et al.,
2010; Elinav et al., 2011; Huber et al., 2012; Salcedo et al.,
2010; Zaki et al., 2010). However, because IL-18 is mainly pro-
duced by intestinal epithelial cells (Dupaul-Chicoine et al.,
2010; Zaki et al., 2010) and IL-18 mRNA expression is moder-
ately increased in Ripk3/ mice, IL-18 is unlikely to contribute
to the phenotypes of Ripk3/ mice.
Mechanistically, RIPK3 mediates this unique and unexpected
function through two distinct signaling mechanisms: nuclear
RelB-p50 translocation and caspase-1-dependent pro-IL-1b
processing. RIPK3 kinase activity was dispensable for RIPK3-
dependent cytokine expression, in contrast to necroptosis.
Rather, ROS may play a role in these non-necrotic RIPK3
signaling functions. Different antioxidants had distinct effects
on RIPK3-dependent cytokine expression. For example, unlike
NAC, the SOD mimetic MnTBAP blocked LPS-induced RelB-
p50, but not caspase 1, activation, whereas the vitamin E analog
Trolox had no effects on LPS-induced cytokine expression. NAC
is a broad-spectrum antioxidant against hydrogen peroxide and
other free radicals such as superoxide, peroxynitrite, hydroxyl
radicals, and peroxyl radicals (Lushchak, 2012). By contrast,
MnTBAP is specific for peroxynitrite and carbonate radicals,
but not for superoxide (Batinic-Haberle et al., 2009). Trolox
mainly prevents the peroxidation of unsaturated lipids in cell
membranes and lipoproteins (Niki, 2014). More work is needed
to clearly define the role of ROS in necrosis-independent
RIPK3 signaling and determine why different antioxidants exhibit
different effects. Nonetheless, these results show that although
the kinase activity of RIPK3 drives necroptosis, the scaffolding
function of RIPK3, possibly through ROS production, is crucial
for necrosis-independent signaling. Because RIPK3 has been
reported to interact with certain mitochondrial enzymes (Wang
et al., 2012; Zhang et al., 2009), it is tempting to speculate that
RIPK3 stimulates a mitochondria oxidative burst to facilitate
ROS-dependent signaling.
Sensitivity to DSS-induced colitis is strongly influenced by in-
testinal microbiota (Elinav et al., 2011). For example, Il18/mice
possess a colitogenic gut microbiota that is transmissible to
co-housed mice (Elinav et al., 2011). Metagenomic analysis
revealed subtle differences in intestinal microbiota between
separately housed Ripk3+/+ and Ripk3/ mice. For example,
the number of bacteroidaceae is decreased, whereas lactobacil-laceae is increased inRipk3/mice compared toRipk3+/+ mice.
In fact, variation was observed in mice that had the same geno-
type but were housed in different cages. However, differences
in microbiota are unlikely to contribute to the phenotypes of
Ripk3/ mice because littermates, mice nursed by the same
foster mother, and co-housed mice exhibited similar sensi-
tivities to DSS. Moreover, adoptive transfer of Ripk3+/+, but not
Ripk3/, DCs partially rescued cytokine expression in Ripk3/
mice, a result that cannot be explained by differences in micro-
biota. As such, we favor a model in which DC-intrinsic functional
differences rather than commensal microbiota dictate the tissue
repair response of Ripk3/ mice.
DCs are important sentinels that maintain immune homeosta-
sis through the expression of immunomodulatory cytokines.
Colitis was significantly more severe when DCs were selectively
depleted, highlighting the protective role of DCs against colitis
(Qualls et al., 2009). We propose that the high RIPK3 and RelB
expression in BMDCs, but not BMDMs, explains why RIPK3 is
uniquely required for BMDC functions. Importantly, DC subsets
in the intestinal lamina propria also highly express RIPK3, in sim-
ilarity to expression seen in BMDCs (unpublished observation).
RIPK3 expression is highly inducible in different immune effec-
tors. Thus, physiological cues that modulate RIPK3 expression
might determine not only cellular sensitivity to necrosis, but
also cytokine responses by distinct immune effectors.
EXPERIMENTAL PROCEDURES
Animal Experiments
All mice were housed in a specific pathogen-free facility at the University of
Massachusetts Medical School (UMMS). Ripk3/ mice were backcrossed
to a C57BL/6J background for more than ten generations and were confirmed
by SNP analyses to be >99.95% on the C57BL/6J background. Female litter-
mates from Ripk3+/ crosses were used for the experiments. After littermates
were weaned, bedding materials from different cages were mixed twice a
week so that differences in intestinal microbial environment would be further
minimized. All animal experiments were approved by the institutional animal
care and use committee. For induction of colitis, female mice (9–11 weeks)
were administered 3% DSS (MP Biomedicals, molecular mass 36,000-
50,000 Da) in the drinking water for 7 days, followed by 7 days of regular water.
The DSS water was replaced on days 3 and 5. Where indicated, mice were
injected intraperitoneally with 50 mg IL-22-Fc (PRO312045), mouse isotype-
matched control antibody (10D9) (kind gifts from Dr. Ouyang, Genentech), or
recombinant mouse IL-23 (0.5 mg) and/or IL-1b (50 ng) (Biolegend). For the
DC adoptive transfer experiment, BMDCs were treated with 100 ng/ml LPS
for 3 hr and then washed with PBS twice so that LPS would be removed.
One million stimulated BMDCs were intraperitoneally injected into DSS-
treated mice on day 5. In all animal experiments, body weight was monitored
throughout the studies, and theweight at the beginning of the experiments was
normalized as 100%. Ripk3/Casp8/ mice were obtained from Dr. K Fitz-
gerald (UMMS).
Histopathology and Immunohistochemistry
The entire colon was excised so that colon length could be measured. Distal
colons were washed with PBS, fixed in 10% buffered formalin, and embedded
in paraffin. Tissue sections were stained with hematoxylin & eosin (H&E).
Histology was scored by two independent gastrointestinal pathologists in a
blinded manner with a semiquantitative scoring system as follows. Presence
of ulcer: 0 = none, 1 = punctate, 2 = minimal, 3 = moderate, 4 = widespread.
Presence of inflammation: 0 = none, 1 = minimal, 2 = mild, 3 = moderate,
4 = severe. Extent of inflammation: 0 = none, 1 = mucosal, 2 = mucosal + sub-
mucosal, 3 = mucosal + submucosal + muscle penetrate, 4 = full thickness
involvement. The total histopathological score was determined by summation
of the scores from each category. Immunohistochemical staining wasImmunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc. 575
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(Abcam), rat anti-F4/80 (Serotec), rabbit anti-Ki67 (Abcam), rabbit anti-active
caspase 3, and rabbit anti-phospho-STAT3 (Tyr 705) (Cell Signaling) anti-
bodies. A liver section was prepared 3 hr after intraperitoneal injection of
anti-mouse Fas antibody (Jo2; BD Biosciences) at a dose of 0.5 mg/kg body
weight intoWTmice as a positive control for active caspase-3 staining. TUNEL
staining was performed with an in situ cell-death detection kit, POD (Roche),
according to the manufacturer’s instructions. For CD3 scoring, ten visual
fields/lamina propria/colon of five mice/group were analyzed. For F4/80
scoring, ten visual fields/colon of five mice/group were analyzed. For Ki67
scoring, six to ten crypts/colon of three to five mice/group were analyzed.
For TUNEL staining, ten visual fields/colon of three control mice and seven
to nine DSS-treated mice were analyzed.
Quantitative PCR (Q-PCR)
Total RNA was extracted from colon tissues or cells with the RNeasy kit
(QIAGEN). cDNA was synthesized with Superscript III (Invitrogen). Real-time
PCR analysis via iQ SYBR Green supermix (Bio-Rad Laboratories) was
performed on a C1000 thermal cycler and CFX96 real-time system (Bio-Rad
Laboratories). Primers used in this study are summarized in the Supplemental
Experimental Procedures. TATA box binding protein (TBP) was chosen as the
internal control for the qPCR experiments out of many housekeeping genes
tested (b-actin, glyceraldehyde-3-phosphate dehydrogenase, b-glucuroni-
dase, hydroxymethylbilane synthase, hypoxanthine-guanine phosphoribosyl-
transferase 1, tubuliln a1, and TBP) because it shows minimal variations
among samples (data not shown).
Generation of BM Radiation Chimera
For collection of BM cells from femur and tibia, flushing was performed with
RPMI1640 media supplemented with 10% FCS, 2 mM glutamine, 100 units/
ml penicillin, and 100 mg/ml streptomycin. T and B cells were depleted by
MACS separation on LD columns after staining of BM cells with biotin-labeled
anti-CD3 (BD Biosciences) and biotin-labeled anti-CD19 (eBiosciences)
antibodies followed by streptavidin microbeads (Miltenyi Biotech). Cell sus-
pension containing 2.5 3 106 cells (200 ul) was intravenously injected into
the irradiated mice (950 rad). For two weeks after engraftment, mice were
given antibiotic water (containing Trimethoprim and Sulfamethoxazole). Seven
weeks after transplantation, the mice were given 3% DSS, and leukocytes
were prepared via tail bleeding and stained with FITC-labeled anti-CD45.1
(BD Biosciences) in the case of Ripk3+/+ cells and with Pacific-blue-labeled
anti-CD45.2 (BioLegend) antibodies in the case of Ripk3/ cells. The cells
were analyzed by LSRII (BD Biosciences).
Generation and Stimulation of BMDCs and BMDMs
For BMDCs, 103 106 BM cells were plated in a 10 cm tissue-culture dish and
cultured for a week with 10 ng/ml GM-CSF (BioLegend) and 5 ng/ml IL-4 (Bio-
source) in RPMI1640 media supplemented with 10% FCS, 2 mM Glutamine,
100 units/ml penicillin, and 100 mg/ml streptomycin. Fresh GM-CSF and IL-4
were added on day 4. Floating cells were collected, plated out, and subjected
to subsequent experimental analyses. For BMDMs, 10 3 106 BM cells were
plated in a 10 cm tissue culture dish and cultured for a week in L929-condi-
tioned media. Fresh L929-conditioned media were added on day 4. Attached
macrophages were plated out and subjected to subsequent experimental
analyses. Purified LPS from Invivogen was used for all experiments. In some
experiments, BMDCs were pretreated with RIPK3 kinase inhibitor GSK’843
(GlaxoSmithKline) (Kaiser et al., 2013), Necrostatin-1 (Nec-1) (Enzo Life Sci-
ences), z-YVAD-fmk (Enzo Life Sciences), N-acetyl cysteine (NAC) (Calbio-
chem), MnTBAP (Enzo Life Sciences), and Trolox (Enzo Life Sciences) for
1 hr prior to LPS stimulation. After stimulation, culture media and cells were
used for ELISA, RNA, and protein analyses.
Isolation of Lamina Propria Mononuclear Cells from Intestine
Colon was harvested from DDS-treated mice on day 7. After feces were
removed with PBS, the intestine was longitudinally opened and cut into small
pieces. The tissue pieces were incubated in predigestion solution (DMEM
media supplementedwith 4%FCS, 25mMHEPES, 1.5mg/ml Dispase II, peni-
cillin, and streptomycin) for 20min at 37Cwith slow shaking. After filtering, the
residual tissue pieces were subsequently incubated in digestion solution576 Immunity 41, 567–578, October 16, 2014 ª2014 Elsevier Inc.(DMEM media supplemented with 4% FCS, 25 mM HEPES, 0.5 mg/ml Colla-
genase IV, 1mg/ml Dispase II, 0.5mg/ml DNase I, penicillin, and streptomycin)
for 20min at 37Cwith slow shaking. After filtering, the filtrate was subjected to
Percoll density-gradient separation. LPMCs at the interphase of the two Per-
coll solutions were collected and subjected to flow-cytometric analysis. The
cells were analyzed by LSRII (BD Biosciences). For active caspase-3 and
TUNEL staining, a PE active caspase-3 apoptosis kit (BD Biosciences) and
an in situ fluorescent cell death detection kit (Roche) were used, respectively.
Measurement of Cytokine Secretion
TNF, MCP1, IL-6, and IL-1b were measured with BD OptEIA ELISA sets (BD
Biosciences). IL-23 and IL-22 were measured with Mouse ELISA MAX Deluxe
sets (BioLegend).
Statistical Analysis
p values were calculated with a Mann-Whitney test or a two-way repeated-
measures ANOVA. p values lower than 0.05 were considered statistically
significant.
SUPPLEMENTAL INFORMATION
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